Business
Alkermes plc Reports Third Quarter 2021 Financial Results
-- Third Quarter Revenues of $294.1 Million Reflect 11% Growth Year-Over-Year -- -- Diluted GAAP Loss per Share of $0.18 and Diluted Non-GAAP Earnings per
About this update from Alkermes Plc
[{"type":"text","content":"-- Third Quarter Revenues of $294.1 Million Reflect 11% Growth Year-Over-Year --\n -- Diluted GAAP Loss per Share of $0.18 and Diluted Non-GAAP Earnings per Share of $0.14 --\n -- Company Reiterates Financial Expectations for 2021 --\n\n\n DUBLIN, Oct. 27, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2021.\n\"We have made significant strides across our commercial and development portfolios over the course of 2021. With the recent commercial launch of LYBALVI®, we have expanded our psychiatry franchise and added an important new growth opportunity that leverages our experience and capabilities in the antipsychotic market. Within our development pipeline, we initiated clinical studies designed to support potential registration of nemvaleukin in mucosal melanoma and platinum-resistant ovarian cancer. We also initiated a phase 1 study of ALKS 1140 and advanced our preclinical orexin 2 receptor agonist program. Each of these important achievements demonstrates the continued execution of our strategy to advance differentiated medicines in neuroscience and oncology,\" said Richard Pops, Chief Executive Officer of Alkermes. \"As we look ahead, we believe we are well-positioned to deliver long-term growth and value creation, driven by our diversified commercial business, our advancing development pipeline and our focus on profitability.\" \nQuarter Ended Sept. 30, 2021 Financial Results\nRevenues\n- Total revenues for the quarter were $294.1 million. This compared to $265.0 million for the same period in the prior year.\n- Net sales of proprietary products for the quarter were $157.7 million, compared to $142.7 million for the same period in the prior year.\nNet sales of VIVITROL® were $88.8 million, compared to $80.3 million for the same period in the prior year, representing an increase of approximately 11%. Net sales of ARISTADA®i were $68.9 million, compared to $62.4 million for the same period in the prior year, representing an increase of approximately 10%. - Manufacturing and royalty revenues for the quarter were $136.3 million, compared to $120.4 million for the same period in the prior year. \nManufacturing and royalty revenues from INVEGA SUSTENNA®/XEPLION®, INVEGA TRINZA®/TREVICTA®, and RISPERDAL CONSTA® were $90.3 million, compared to $87.9 million for the same per...